Go Pro
NASDAQ:ESLA

Estrella Immunopharma Q4 2025 Earnings Report

Estrella Immunopharma logo
$0.82 -0.02 (-1.80%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$0.83 +0.00 (+0.50%)
As of 07:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Estrella Immunopharma EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Estrella Immunopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Estrella Immunopharma Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Estrella Immunopharma's next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules.

Conference Call Resources

Estrella Immunopharma Earnings Headlines

What is Zacks Research's Forecast for ESLA Q2 Earnings?
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
Estrella Immunopharma Inc.
See More Estrella Immunopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Estrella Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Estrella Immunopharma and other key companies, straight to your email.

About Estrella Immunopharma

Estrella Immunopharma (NASDAQ:ESLA), a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

View Estrella Immunopharma Profile